Your browser is no longer supported. Please, upgrade your browser.
Settings
ILMN Illumina, Inc. daily Stock Chart
ILMN [NASD]
Illumina, Inc.
IndexS&P 500 P/E54.89 EPS (ttm)4.85 Insider Own0.50% Shs Outstand146.34M Perf Week-1.28%
Market Cap38.96B Forward P/E48.25 EPS next Y5.52 Insider Trans-14.86% Shs Float146.25M Perf Month9.72%
Income717.00M PEG2.98 EPS next Q1.10 Inst Own92.60% Short Float1.48% Perf Quarter14.05%
Sales2.94B P/S13.27 EPS this Y89.40% Inst Trans-0.22% Short Ratio2.72 Perf Half Y23.62%
Book/sh20.46 P/B13.01 EPS next Y14.20% ROA11.00% Target Price259.31 Perf Year53.21%
Cash/sh16.22 P/C16.42 EPS next 5Y18.39% ROE20.00% 52W Range167.98 - 273.93 Perf YTD21.85%
Dividend- P/FCF60.59 EPS past 5Y39.20% ROI9.90% 52W High-2.82% Beta0.87
Dividend %- Quick Ratio2.40 Sales past 5Y19.10% Gross Margin68.00% 52W Low58.48% ATR6.30
Employees6200 Current Ratio2.70 Sales Q/Q30.80% Oper. Margin26.30% RSI (14)59.72 Volatility1.93% 2.14%
OptionableYes Debt/Eq0.44 EPS Q/Q-43.70% Profit Margin19.30% Rel Volume0.82 Prev Close270.83
ShortableYes LT Debt/Eq0.24 EarningsApr 24 AMC Payout0.00% Avg Volume797.72K Price266.22
Recom2.00 SMA202.73% SMA507.27% SMA20018.69% Volume655,470 Change-1.70%
Feb-05-18Upgrade Citigroup Neutral → Buy
Jan-31-18Upgrade First Analysis Sec Equal-Weight → Overweight $277
Jan-05-18Initiated BTIG Research Neutral
Jan-05-18Downgrade William Blair Outperform → Mkt Perform
Jan-02-18Upgrade Wells Fargo Market Perform → Outperform
Oct-25-17Upgrade Robert W. Baird Neutral → Outperform $184 → $228
Oct-23-17Upgrade Janney Sell → Neutral
Oct-23-17Upgrade Deutsche Bank Hold → Buy $195 → $250
Sep-26-17Resumed Goldman Neutral $200
Aug-07-17Upgrade Canaccord Genuity Hold → Buy $170 → $215
Aug-02-17Upgrade First Analysis Sec Underweight → Equal-Weight
Apr-26-17Reiterated Cantor Fitzgerald Neutral $155 → $170
Mar-20-17Upgrade Leerink Partners Mkt Perform → Outperform
Feb-01-17Reiterated UBS Buy $180 → $185
Jan-18-17Initiated Deutsche Bank Hold $160
Jan-10-17Upgrade BofA/Merrill Neutral → Buy
Jan-06-17Upgrade CL King Neutral → Buy
Dec-07-16Reiterated Morgan Stanley Underweight $115 → $100
Nov-10-16Resumed Leerink Partners Mkt Perform
Nov-02-16Downgrade First Analysis Sec Equal-Weight → Underweight $130 → $116
May-25-18 10:15AM  Abbott Presents Positive Study Results for Tendyne Device Zacks
09:57AM  5 Top Efficient Stocks to Keep on Your Radar Zacks
09:24AM  AbbVie's Imbruvica's Phase III Study Meets Primary Endpoint Zacks
May-24-18 05:00PM  Kaskela Law LLC Announces Investigation of Illumina, Inc. on Behalf of Stockholders Business Wire
04:18PM  Agios (AGIO) Progressing Well on Pipeline Amid Competition Zacks
10:57AM  Myriad Genetics' Prolaris Expands on New Coverage Decisions Zacks
09:26AM  Abbott Gets FDA Nod for XIENCE Sierra, To Boost Vascular Wing Zacks
08:45AM  Why is Illumina (ILMN) Up 13.5% Since Its Last Earnings Report? Zacks
May-23-18 03:05PM  Dr. Reddy's (RDY) Q4 Earnings Fall, Revenues Decline Y/Y Zacks
10:10AM  Medtronic (MDT) Q4 Earnings: Can Spine Division Turn Around? Zacks
09:16AM  Zimmer Biomet New System Gets FDA Nod, to Boost Spine Wing Zacks
May-22-18 12:01PM  Inovio Initiates Phase II Study on Pipeline Drug VGX-3100 Zacks
10:12AM  Will Solid Diabetes Arm Drive Medtronic's (MDT) Q4 Earnings? Zacks
07:10AM  Free Daily Technical Summary Reports on Valeritas and Three Other Medical Supplies Stocks ACCESSWIRE
May-21-18 08:37PM  Chinese investors lead another monster round into this early cancer detection company American City Business Journals
11:09AM  AstraZeneca's Lokelma Gains FDA Nod to Treat Hyperkalemia Zacks
11:04AM  ResMed Releases Positive U.S. & U.K. Study Data on COPD Zacks
09:31AM  Here's Why You Should Invest in Illumina (ILMN) Stock Now Zacks
09:27AM  Will Strong RTG Arm Drive Medtronic's (MDT) Q4 Earnings? Zacks
May-18-18 03:21PM  Pfizer's Epilepsy Drug Lyrica Succeeds in Pediatric Study Zacks
08:17AM  5 Things Every Illumina Investor Needs to Know Motley Fool
May-17-18 09:42AM  QIAGEN (QGEN) Banks on Test Menu Expansion, Competition Stiff Zacks
09:33AM  Medtronic Initiates Study on DES for Expanded Use in the US Zacks
May-16-18 05:00PM  Testing for all lung cancer mutations at once found cost effective-study Reuters
08:52AM  Illumina Takes Over Edico Genome, Fortifies NGS Platform Zacks
May-15-18 10:45AM  Roche's Actemra Gets FDA Nod for Subcutaneous Formulation Zacks
09:30AM  3 Stocks to Buy and Hold for Decades Motley Fool
09:00AM  Illumina Acquires Edico Genome to Accelerate Genomic Data Analysis Business Wire
May-11-18 08:39AM  Zacks.com featured highlights include: Marine Products, Nutrisystem, Exelixis, Illumina and Baxter Zacks
May-10-18 08:47AM  5 Winning Stocks With Superb Efficiency Level Zacks
May-09-18 05:07PM  Should You Be Tempted To Sell Illumina Inc (NASDAQ:ILMN) At Its Current PE Ratio? Simply Wall St.
07:34AM  Zacks.com featured highlights include: Caterpillar, WellCare Health, Intuit, Cardtronics and Illumina Zacks
May-08-18 03:52PM  Perrigo (PRGO) Misses on Earnings in Q1, Reiterates View Zacks
08:30AM  Today's Research Reports on Trending Tickers: Sorrento Therapeutics and Illumina ACCESSWIRE
07:50AM  Free Post Earnings Research Report: Illuminas Quarterly Revenue Surged 31%; Adjusted EPS Soared 127% ACCESSWIRE
06:55AM  5 Top Stocks Showing Promise of an Earnings Beat Zacks
May-07-18 04:41PM  The Biggest Movers: Illumina Shines; International Flavors' Iffy Results Barrons.com
04:05PM  Seven Stocks That Have Refused To Go Down Investor's Business Daily
03:28PM  Agios (AGIO) Q1 Loss Wider than Expected, Revenues Miss Zacks
01:54PM  Illumina Stock Upgraded: What You Need to Know Motley Fool
May-02-18 09:00AM  Illumina to Webcast Upcoming Investor Conference Presentation Business Wire
Apr-29-18 01:30AM  EQUITY ALERT: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties By Management of Illumina, Inc. ILMN Business Wire
Apr-27-18 07:44AM  Zacks.com highlights: Illumina, Alarm.com Holdings, Copart and Vanda Pharmaceuticals Zacks
Apr-26-18 09:54PM  Edited Transcript of ILMN earnings conference call or presentation 24-Apr-18 9:00pm GMT Thomson Reuters StreetEvents
06:18PM  Visa, Smart Global Holdings, Illumina Added To IBD 50 As Market Moves Higher Investor's Business Daily
12:35PM  4 Top Efficient Stocks to Buy for Stellar Returns InvestorPlace
10:20AM  4 Top Efficient Stocks to Buy for Stellar Returns Zacks
07:40AM  Blog Exposure - Intec Pharma Shares Phase-1 PK and Safety Data from Accordion Pill Carbidopa/Levodopa at AAN Annual Meeting ACCESSWIRE
06:32AM  3 Biggest Stories That Illumina's Q1 Earnings Didn't Tell Motley Fool
Apr-25-18 03:49PM  Illumina (ILMN) Q1 2018 Earnings Conference Call Transcript Motley Fool
12:12PM  Illumina (ILMN) Beats on Q1 Earnings, Lifts '18 Guidance Zacks
07:11AM  3 Stocks to Watch on Wednesday: Edwards Lifesciences Corp (EW), Illumina, Inc. (ILMN) and Tesla Inc (TSLA) InvestorPlace
06:01AM  Illumina Inc. First-Quarter Results: NovaSeq Still the Gift That Keeps on Giving Motley Fool
Apr-24-18 05:17PM  After-hours buzz: TXN, WYNN, EW & more CNBC
04:16PM  Illumina: 1Q Earnings Snapshot Associated Press
04:05PM  Illumina Reports Financial Results for First Quarter of Fiscal Year 2018 Business Wire
12:00PM  Illumina, Inc. to Host Earnings Call ACCESSWIRE
Apr-23-18 09:20AM  Update: Lawsuit for Investors in Illumina, Inc. (NASDAQ: ILMN) Shares Announced by Shareholders Foundation ACCESSWIRE
Apr-13-18 10:50PM  ILLUMINA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Illumina, Inc. - ILMN PR Newswire
04:51PM  Illumina shares advance on Bristol-Myers cancer drug collaboration MarketWatch
04:17PM  Bristol Partners With Illumina On Diagnostic Test To Use With Opdivo Forbes
04:15PM  Bristol-Myers Squibb and Illumina Announce Strategic Collaboration to Develop and Commercialize Companion Diagnostics for Bristol-Myers Squibbs Oncology Immunotherapies Business Wire
Apr-12-18 11:00AM  Can Solid Overall Growth Drive Illumina's (ILMN) Q1 Earnings? Zacks
07:19AM  Is PowerShares Dynamic Biotechnology & Genome Portfolio (PBE) a Hot ETF Right Now? Zacks
Apr-10-18 07:14PM  As Illumina moves into new Peninsula digs, it's got a surprise tenant (Video) American City Business Journals
08:06AM  Loxo, Illumina to partner for diagnostic tool targeting cancer Reuters
07:44AM  Loxo and Illumina in partnership over diagnostic for cancer drug Reuters
06:45AM  Loxo Oncology and Illumina to Partner on Developing Next-Generation Sequencing-Based Pan-Cancer Companion Diagnostics GlobeNewswire
06:45AM  Illumina and Loxo Oncology to Partner on Developing Next-Generation Sequencing-Based Pan-Cancer Companion Diagnostics Business Wire
04:00AM  Illumina to Announce First Quarter 2018 Financial Results on Tuesday, April 24, 2018 Business Wire
Apr-04-18 06:04AM  The 3 Most Expensive Large Healthcare Stocks on the Market: Are They Worth Their Hefty Price Tags? Motley Fool
Mar-30-18 10:50PM  ILLUMINA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Illumina, Inc. - ILMN Business Wire
Mar-27-18 02:38PM  How Did Illumina Incs (NASDAQ:ILMN) 22.84% ROE Fare Against The Industry? Simply Wall St.
Mar-22-18 04:04PM  The Shuman Law Firm Investigates Illumina, Inc. Business Wire
Mar-20-18 06:31AM  Illumina Just Hit an All-Time High: Buy, Sell, or Hold? Motley Fool
Mar-14-18 09:17AM  3 Things Investors Should Love About Illumina Motley Fool
Mar-13-18 11:09AM  Illumina Banks on Product Launches & Strategic Partnerships Zacks
Mar-12-18 04:05PM  Illumina Names Dr. Phil Febbo Chief Medical Officer Business Wire
Mar-05-18 07:07PM  BRIEF-Anhui Anke Biotechnology's Unit Obtains Exclusive Distribution Rights In China For Verogen's Products Reuters
Mar-01-18 10:00AM  Silicon Valley-based Illumina spinoff raising $200M for genetics app store American City Business Journals
07:30AM  Helix holds first close on a planned $200 million investment in its genetic services marketplace TechCrunch
Feb-28-18 09:15AM  5 of the Most Disruptive Stocks in Healthcare Motley Fool
09:00AM  Mérieux Développement and Paladin Capital Group Co-lead $55.5 Million Series C Financing Into Inscripta, a Leading Company in the Field of Gene Editing, in Preparation for Platform Expansion and Commercial Launch PR Newswire
Feb-27-18 09:00AM  Illumina to Webcast Upcoming Investor Conference Presentation Business Wire
Feb-26-18 09:15PM  442 Top Funds Own This Genomics Stock Seeking New China FDA Approval Investor's Business Daily
Feb-23-18 12:29PM  3 Top DNA Stocks to Consider Buying Now Motley Fool
Feb-20-18 09:00AM  Microsoft Chairman John Thompson Talks Cloud Competition, Diversity, and New Rubrik Board Seat Fortune
Feb-14-18 07:35AM  New Research Coverage Highlights Illumina, Vectren, Chemours, Fastenal, Norwegian Cruise Line, and Globalstar Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Feb-13-18 06:48AM  Illumina Inc (ILMN) Files 10-K for the Fiscal Year Ended on December 31, 2017 GuruFocus.com
Feb-08-18 10:03AM  Illumina Banks on Strategic Partnerships, Competition Rife Zacks -5.27%
07:10AM  Free Post Earnings Research Report: Illuminas Quarterly Revenue Surged 26%; Non-GAAP EPS Soared 69.4% ACCESSWIRE
Feb-05-18 08:49AM  Billionaire Fund Managers Are Bullish On These Biotech Stocks Insider Monkey
Feb-02-18 07:00AM  Cornell Chases Lucrative Royalties Lost on Secret Side Deals Bloomberg
Jan-31-18 08:30AM  Illumina (ILMN) Tops Q4 Earnings & Revenues, Issues Guidance Zacks
06:31AM  Illumina Keeps the Momentum Going With Solid Fourth-Quarter Earnings Growth Motley Fool
Jan-30-18 04:31PM  Illumina beats Street 4Q forecasts Associated Press
04:05PM  Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2017 Business Wire
01:00PM  Stocks Down, More Homebuilders In Trouble; When To Sell Apple Investor's Business Daily
10:30AM  Illumina, Inc. to Host Earnings Call ACCESSWIRE
09:01AM  Is Illumina Incs (NASDAQ:ILMN) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St.
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array. The company also provides various library preparation and sequencing kits to simplify workflows and accelerate analysis; and genome sequencing, genotyping, and noninvasive prenatal testing, as well as products support services. It serves genomic research centers, academic institutions, government laboratories, and hospitals; and pharmaceutical, biotechnology, agrigenomics, and commercial molecular diagnostic laboratories, as well as consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. It operates in North America, Europe, Latin America, the Asia-Pacific region, the Middle East, and South Africa. The company has a strategic partnership with Loxo Oncology, Inc. to develop and commercialize a multi-gene panel for broad tumor profiling; and strategic collaboration with Bristol-Myers Squibb Company. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
EASTHAM KARINDirectorMay 21Sale269.801,000269,80212,288May 22 05:23 PM
EPSTEIN ROBERT SDirectorMay 21Sale271.00500135,5006,588May 22 05:25 PM
Ronaghi MostafaSr VP & CTOMay 16Option Exercise28.4510,000284,50080,996May 18 07:39 PM
Ronaghi MostafaSr VP & CTOMay 16Sale267.7110,0002,677,13570,996May 18 07:39 PM
deSouza Francis APresident and CEOMay 14Sale268.632,100564,12486,471May 16 09:37 PM
FLATLEY JAY TDirectorMay 14Sale268.001,460391,2804,000May 16 09:40 PM
OSTADAN OMEADEVP Ops, Products, StrategyMay 02Sale242.601,314318,77627,153May 04 06:53 PM
BOWMAN A BLAINEDirectorMay 01Option Exercise55.143,000165,42619,868May 03 06:23 PM
BOWMAN A BLAINEDirectorMay 01Sale241.453,000724,33616,868May 03 06:23 PM
Van Oene MarkSVP Chief Commercial OfficerApr 12Sale238.481,400333,87212,217Apr 13 07:30 PM
Dadswell CharlesSr VP & General CounselApr 03Sale230.9111626,7867,875Apr 04 07:32 PM
BOWMAN A BLAINEDirectorApr 02Option Exercise44.513,000133,53019,868Apr 04 07:29 PM
BOWMAN A BLAINEDirectorApr 02Sale230.133,000690,38316,868Apr 04 07:29 PM
ARNOLD FRANCESDirectorMar 15Sale252.2625063,06510,189Mar 15 07:56 PM
ARNOLD FRANCESDirectorMar 08Sale241.5025060,37510,439Mar 08 07:50 PM
Stapley MarcEVP Strategy & Corp DevelopmtMar 06Sale233.642,000467,28813,787Mar 08 07:45 PM
EASTHAM KARINDirectorMar 05Option Exercise71.092,000142,18015,288Mar 06 07:17 PM
EASTHAM KARINDirectorMar 05Sale229.372,000458,73513,288Mar 06 07:17 PM
Dadswell CharlesSr VP & General CounselMar 05Sale227.1714532,9407,991Mar 06 07:13 PM
OSTADAN OMEADEVP Ops, Products, StrategyMar 02Sale222.661,329295,91628,467Mar 05 09:03 PM
BOWMAN A BLAINEDirectorMar 01Option Exercise44.513,000133,53019,868Mar 05 08:12 PM
BOWMAN A BLAINEDirectorMar 01Sale227.013,000681,02816,868Mar 05 08:12 PM
EPSTEIN ROBERT SDirectorFeb 28Sale231.2525057,8137,088Mar 02 07:06 PM
Van Oene MarkSVP Chief Commercial OfficerFeb 16Sale228.851,408322,22113,617Feb 20 09:26 PM
Van Oene MarkSVP Chief Commercial OfficerFeb 15Option Exercise0.002,124015,760Feb 20 09:26 PM
Stapley MarcEVP Strategy & Corp DevelopmtFeb 15Option Exercise0.006,257032,430Feb 20 09:23 PM
Ronaghi MostafaSr VP & CTOFeb 15Option Exercise0.004,740072,785Feb 20 09:18 PM
OSTADAN OMEADEVP Ops, Products, StrategyFeb 15Option Exercise0.006,257032,355Feb 20 09:16 PM
FLATLEY JAY TDirectorFeb 15Option Exercise0.0026,5420413,706Feb 20 09:13 PM
deSouza Francis APresident and CEOFeb 15Option Exercise0.0010,238092,990Feb 20 09:10 PM
Dadswell CharlesSr VP & General CounselFeb 15Option Exercise0.003,79209,455Feb 20 09:07 PM
Stapley MarcEVP Strategy & Corp DevelopmtFeb 06Sale216.872,000433,74126,052Feb 08 06:23 PM
Dadswell CharlesSr VP & General CounselFeb 05Sale221.451,610356,5355,581Feb 05 07:07 PM
BOWMAN A BLAINEDirectorFeb 01Option Exercise44.513,000133,53019,868Feb 05 07:05 PM
BOWMAN A BLAINEDirectorFeb 01Sale230.823,000692,44816,868Feb 05 07:05 PM
EPSTEIN ROBERT SDirectorJan 29Option Exercise51.171,00051,1708,588Jan 30 08:36 PM
EPSTEIN ROBERT SDirectorJan 29Sale244.181,250305,2257,338Jan 30 08:36 PM
Stapley MarcEVP Strategy & Corp DevelopmtJan 17Sale242.332,000484,66728,315Jan 18 07:01 PM
FLATLEY JAY TDirectorJan 16Sale243.7215,0003,655,763437,899Jan 18 06:50 PM
Dadswell CharlesSr VP & General CounselJan 03Sale224.5014532,5537,411Jan 04 06:53 PM
FLATLEY JAY TDirectorJan 02Sale223.4020,0004,468,090452,899Jan 03 09:16 PM
EPSTEIN ROBERT SDirectorDec 29Option Exercise51.171,00051,1708,838Jan 02 08:36 PM
EPSTEIN ROBERT SDirectorDec 29Sale217.381,250271,7257,588Jan 02 08:36 PM
FLATLEY JAY TDirectorDec 19Sale215.4820,0004,309,502472,899Dec 21 08:03 PM
FLATLEY JAY TDirectorDec 05Sale212.5520,0004,251,088491,717Dec 07 08:21 PM
Stapley MarcEVP Strategy & Corp DevelopmtDec 04Sale219.882,000439,76427,395Dec 06 05:50 PM
Dadswell CharlesSr VP & General CounselDec 04Sale225.3314532,6736,388Dec 06 05:48 PM
OSTADAN OMEADEVP Ops, Products, StrategyDec 01Option Exercise37.043,540131,12226,827Dec 05 05:47 PM
EPSTEIN ROBERT SDirectorDec 01Option Exercise51.171,00051,1709,088Dec 05 05:50 PM
OSTADAN OMEADEVP Ops, Products, StrategyDec 01Sale226.913,540803,26723,287Dec 05 05:47 PM
EPSTEIN ROBERT SDirectorDec 01Sale226.551,250283,1887,838Dec 05 05:50 PM
FLATLEY JAY TDirectorNov 21Option Exercise70.8215,0001,062,300531,717Nov 24 05:31 PM
FLATLEY JAY TDirectorNov 21Sale211.3520,0004,227,023511,717Nov 24 05:31 PM
Van Oene MarkSVP Chief Commercial OfficerNov 15Sale206.21183,71211,673Nov 15 08:02 PM
Stapley MarcEVP Strategy & Corp DevelopmtNov 15Sale205.482,000410,95829,395Nov 16 05:58 PM
Van Oene MarkSVP Chief Commercial OfficerNov 13Sale207.781,232255,98511,691Nov 15 08:02 PM
FLATLEY JAY TDirectorNov 07Option Exercise70.8220,0001,416,400536,717Nov 08 07:37 PM
FLATLEY JAY TDirectorNov 07Sale210.5920,0004,211,749516,717Nov 08 07:37 PM
Dadswell CharlesSr VP & General CounselNov 03Sale207.881,609334,4797,217Nov 07 08:45 PM
Stapley MarcEVP Strategy & Corp DevelopmtOct 26Sale206.882,000413,75932,679Oct 30 08:00 PM
FLATLEY JAY TDirectorOct 24Option Exercise70.8220,0001,416,400539,176Oct 26 06:51 PM
FLATLEY JAY TDirectorOct 24Sale210.4320,0004,208,568519,176Oct 26 06:51 PM
Van Oene MarkSVP Chief Commercial OfficerOct 12Sale207.211,250259,01313,929Oct 13 05:31 PM
FLATLEY JAY TDirectorOct 10Option Exercise70.8220,0001,416,400539,176Oct 12 07:20 PM
FLATLEY JAY TDirectorOct 10Sale203.2720,0004,065,386519,176Oct 12 07:20 PM
Dadswell CharlesSr VP & General CounselOct 03Sale202.2314529,3238,826Oct 05 05:35 PM
FLATLEY JAY TDirectorSep 26Option Exercise70.8220,0001,416,400539,176Sep 28 07:01 PM
FLATLEY JAY TDirectorSep 26Sale200.1620,0004,003,138519,176Sep 28 07:01 PM
Van Oene MarkSVP Chief Commercial OfficerSep 12Option Exercise29.445,838171,87124,908Sep 14 06:05 PM
FLATLEY JAY TDirectorSep 12Option Exercise70.8220,0001,416,400539,176Sep 14 06:08 PM
FLATLEY JAY TDirectorSep 12Sale211.1120,0004,222,121519,176Sep 14 06:08 PM
Van Oene MarkSVP Chief Commercial OfficerSep 12Sale211.339,7292,056,03415,179Sep 14 06:05 PM
Ronaghi MostafaSr VP & CTOSep 07Option Exercise44.3820,000887,60086,725Sep 08 05:41 PM
Ronaghi MostafaSr VP & CTOSep 07Sale210.0020,0004,200,00066,725Sep 08 05:41 PM
Stapley MarcEVP & Chief Administrative OfcSep 05Sale205.932,000411,85734,679Sep 07 07:19 PM
Dadswell CharlesSr VP & General CounselSep 05Sale205.7114529,8288,971Sep 07 07:17 PM
Bouchard MichelChief Accounting OfficerAug 31Sale202.384,774966,17010,387Sep 01 05:34 PM
Bouchard MichelChief Accounting OfficerAug 30Sale200.00616123,20015,161Sep 01 05:34 PM
FLATLEY JAY TDirectorAug 29Option Exercise70.8220,0001,416,400539,176Aug 30 07:58 PM
FLATLEY JAY TDirectorAug 29Sale194.9320,0003,898,692519,176Aug 30 07:58 PM
FLATLEY JAY TDirectorAug 28Sale197.392,540501,370140Aug 30 07:58 PM
FLATLEY JAY TDirectorAug 15Option Exercise70.8220,0001,416,400539,176Aug 17 09:23 PM
FLATLEY JAY TDirectorAug 15Sale194.7320,0003,894,601519,176Aug 17 09:23 PM
OSTADAN OMEADEVP Ops, Products, StrategyAug 07Sale195.261,671326,27924,571Aug 09 08:39 PM
Stapley MarcEVP & Chief Administrative OfcAug 03Sale196.802,000393,60036,641Aug 07 08:32 PM
Dadswell CharlesSr VP & General CounselAug 03Sale197.001,609316,9739,037Aug 07 08:21 PM
FLATLEY JAY TDirectorAug 02Option Exercise70.825,000354,100524,176Aug 03 09:14 PM
Ronaghi MostafaSr VP & CTOAug 02Option Exercise44.3810,000443,80076,585Aug 04 05:13 PM
EASTHAM KARINDirectorAug 02Option Exercise75.6610,800817,12824,388Aug 04 05:44 PM
Bouchard MichelChief Accounting OfficerAug 02Sale194.973,131610,44015,762Aug 04 05:17 PM
Ronaghi MostafaSr VP & CTOAug 02Sale195.0010,0001,950,00066,585Aug 04 05:13 PM
EASTHAM KARINDirectorAug 02Sale195.0010,8002,106,00013,588Aug 04 05:44 PM
FLATLEY JAY TDirectorAug 02Sale188.005,000940,000519,176Aug 03 09:14 PM
FLATLEY JAY TDirectorAug 01Option Exercise70.8215,0001,062,300534,176Aug 03 09:14 PM
FLATLEY JAY TDirectorAug 01Sale172.5715,0002,588,568519,176Aug 03 09:14 PM
FLATLEY JAY TDirectorJul 18Option Exercise70.8215,0001,062,300534,176Jul 20 07:37 PM
FLATLEY JAY TDirectorJul 18Sale170.7715,0002,561,565519,176Jul 20 07:37 PM
Stapley MarcEVP & Chief Administrative OfcJul 14Sale173.562,000347,12338,641Jul 17 08:34 PM
OSTADAN OMEADEVP Ops, Products, StrategyJul 07Sale172.731,672288,80526,242Jul 11 07:29 PM
FLATLEY JAY TDirectorJul 05Option Exercise70.8215,0001,062,300534,176Jul 07 06:10 PM